Defining new surrogate markers for CKD progression.

Homocysteine and C-reactive protein as useful surrogate markers for evaluating CKD risk in adults.

Response to the editorial on "Defining vitamin D deficiency, using surrogate markers".

Surrogate markers in AIDS.

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria.

Obesity and CKD progression: hard facts on fat CKD patients.

Surrogate Markers and Drug Approvals.

Bad medicine: using surrogate markers.

Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.

High HPgV replication is associated with improved surrogate markers of HIV progression.

Metabolite markers of incident CKD risk.

Searching novel diagnostic markers and targets for therapy of CKD.

A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression.

Surrogate markers for time-varying treatments and outcomes.

Surrogate Markers: Lessons from the Next Gen?

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.

Markers for the progression of IgA nephropathy.

Prognostic markers for HIV disease progression.

Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study.

Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression.

Can muscle-kidney crosstalk slow progression of CKD?

Genetic African Ancestry and Markers of Mineral Metabolism in CKD.

A New Comparative-Genomics Approach for Defining Phenotype-Specific Indicators Reveals Specific Genetic Markers in Predatory Bacteria.

Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression.

Effects of dietary interventions on incidence and progression of CKD.

Suggest Documents

Homocysteine and C-reactive protein as useful surrogate markers for evaluating CKD risk in adults.

Response to the editorial on "Defining vitamin D deficiency, using surrogate markers".

Surrogate markers in AIDS.

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria.

Obesity and CKD progression: hard facts on fat CKD patients.

Surrogate Markers and Drug Approvals.

Bad medicine: using surrogate markers.

Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.

High HPgV replication is associated with improved surrogate markers of HIV progression.

Metabolite markers of incident CKD risk.

Searching novel diagnostic markers and targets for therapy of CKD.

A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression.

Surrogate markers for time-varying treatments and outcomes.

Surrogate Markers: Lessons from the Next Gen?

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.

Markers for the progression of IgA nephropathy.

Prognostic markers for HIV disease progression.

Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study.

Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression.

Can muscle-kidney crosstalk slow progression of CKD?

Genetic African Ancestry and Markers of Mineral Metabolism in CKD.

A New Comparative-Genomics Approach for Defining Phenotype-Specific Indicators Reveals Specific Genetic Markers in Predatory Bacteria.

Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression.

Effects of dietary interventions on incidence and progression of CKD.

Defining new surrogate markers for CKD progression.

Recommend Documents

Follow Us